Magazin
AM Business
Info Guide
Directories
Events
Jobs
Das israelische Unternehmen Nano Dimension testet gemeinsam mit Accellta 3D Druck von Stammzellen.
Nano Dimension ist durch seinen 3D Drucker für Leiterbahnen, den Dragonfly 2020, bekannt geworden. So kommt diese Ankündigung mit der Zusammenarbeit mit Accellta, zumindest für mich, überraschend.
Accellta produziert Lösungen zur Kultivierung von Stamm- und anderen Zellen. Gemeinsam haben die beiden Unternehmen einen Proof-of-concept 3D Drucker entwickelt, der Objekte aus Stammzellen produzieren kann.
Amit Dror, CEO von Nano Dimension:
“3D printing of living cells is a technology that is already playing a significant role in medical research, but in order to reach its full potential, for the field to evolve further, there is a need to improve printing speeds, print resolution, cell control and viability as well as cell availability and bio-ink technologies. By combining our high speed, high precision inkjet capabilities with Accellta’s stem cell suspension technologies and induced differentiation capabilities led by a world-renown group of experienced engineers and scientists, we can enable 3D printing at high resolution and high volumes.”
Die 3D inkjet Technologie von Nano Dimension ermöglich es komplexe Strukturen aus mehreren Materialien zu produzieren. Der Prototyp zeigt, dass die Technologie auch nicht vor Bioprinting halt macht.
Dr. Itzchak Angel, Vorstand und CEO von Accellta:
“Accellta and Nano Dimension have joined forces in this initial trial to evaluate and adapt the joint potential of our technologies. We hope and believe that this will bring the mutual capabilities and know-how of both companies to create 3D bioprinting solutions that combine a high precision, high-throughput printer with dedicated bio-ink technologies, derived from stem cells. By enabling high precision 3D bioprinting and differentiation of stem cells into required tissues, our combined technologies have the potential to enable vast areas of development. We are very excited about these initial results and what the future holds.”
